175 related articles for article (PubMed ID: 29299983)
1. Metabolic Enzyme System and Transport Pathways in Chronic Kidney Diseases.
Liu B; Luo F; Luo X; Duan S; Gong Z; Peng J
Curr Drug Metab; 2018; 19(7):568-576. PubMed ID: 29299983
[TBL] [Abstract][Full Text] [Related]
2. [Drug pharmacokinetics in renal failure: What's new?].
Naud J; Dumayne C; Nolin TD; Leblond FA; Pichette V
Nephrol Ther; 2015 Jun; 11(3):144-51. PubMed ID: 25861715
[TBL] [Abstract][Full Text] [Related]
3. The Effects of CKD on Cytochrome P450-Mediated Drug Metabolism.
Ladda MA; Goralski KB
Adv Chronic Kidney Dis; 2016 Mar; 23(2):67-75. PubMed ID: 26979145
[TBL] [Abstract][Full Text] [Related]
4. Effects of chronic renal failure on kidney drug transporters and cytochrome P450 in rats.
Naud J; Michaud J; Beauchemin S; Hébert MJ; Roger M; Lefrancois S; Leblond FA; Pichette V
Drug Metab Dispos; 2011 Aug; 39(8):1363-9. PubMed ID: 21525170
[TBL] [Abstract][Full Text] [Related]
5. Effects of chronic kidney disease and uremia on hepatic drug metabolism and transport.
Yeung CK; Shen DD; Thummel KE; Himmelfarb J
Kidney Int; 2014 Mar; 85(3):522-8. PubMed ID: 24132209
[TBL] [Abstract][Full Text] [Related]
6. The Role of the Kidney in Drug Elimination: Transport, Metabolism, and the Impact of Kidney Disease on Drug Clearance.
Miners JO; Yang X; Knights KM; Zhang L
Clin Pharmacol Ther; 2017 Sep; 102(3):436-449. PubMed ID: 28599065
[TBL] [Abstract][Full Text] [Related]
7. Effects of renal failure on drug transport and metabolism.
Sun H; Frassetto L; Benet LZ
Pharmacol Ther; 2006 Jan; 109(1-2):1-11. PubMed ID: 16085315
[TBL] [Abstract][Full Text] [Related]
8. Emerging Roles of Aryl Hydrocarbon Receptors in the Altered Clearance of Drugs during Chronic Kidney Disease.
Santana Machado T; Cerini C; Burtey S
Toxins (Basel); 2019 Apr; 11(4):. PubMed ID: 30959953
[TBL] [Abstract][Full Text] [Related]
9. Nonrenal drug clearance in CKD: Searching for the path less traveled.
Momper JD; Venkataramanan R; Nolin TD
Adv Chronic Kidney Dis; 2010 Sep; 17(5):384-91. PubMed ID: 20727508
[TBL] [Abstract][Full Text] [Related]
10. The effect of chronic renal failure on drug metabolism and transport.
Dreisbach AW; Lertora JJ
Expert Opin Drug Metab Toxicol; 2008 Aug; 4(8):1065-74. PubMed ID: 18680441
[TBL] [Abstract][Full Text] [Related]
11. Uremic toxins inhibit renal metabolic capacity through interference with glucuronidation and mitochondrial respiration.
Mutsaers HA; Wilmer MJ; Reijnders D; Jansen J; van den Broek PH; Forkink M; Schepers E; Glorieux G; Vanholder R; van den Heuvel LP; Hoenderop JG; Masereeuw R
Biochim Biophys Acta; 2013 Jan; 1832(1):142-50. PubMed ID: 23017367
[TBL] [Abstract][Full Text] [Related]
12. Emerging evidence of the impact of kidney disease on drug metabolism and transport.
Nolin TD; Naud J; Leblond FA; Pichette V
Clin Pharmacol Ther; 2008 Jun; 83(6):898-903. PubMed ID: 18388866
[TBL] [Abstract][Full Text] [Related]
13. In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor.
Reese MJ; Savina PM; Generaux GT; Tracey H; Humphreys JE; Kanaoka E; Webster LO; Harmon KA; Clarke JD; Polli JW
Drug Metab Dispos; 2013 Feb; 41(2):353-61. PubMed ID: 23132334
[TBL] [Abstract][Full Text] [Related]
14. In vitro-in vivo extrapolation of bexarotene metabolism in the presence of chronic kidney disease and acute kidney injury in rat using physiologically based pharmacokinetic modeling and extrapolation to human.
Alsmadi MM; Alzughoul SB
Biopharm Drug Dispos; 2023 Jun; 44(3):221-244. PubMed ID: 36319070
[TBL] [Abstract][Full Text] [Related]
15. Impact of kidney dysfunction on hepatic and intestinal drug transporters.
Droździk M; Oswald S; Droździk A
Biomed Pharmacother; 2021 Nov; 143():112125. PubMed ID: 34474348
[TBL] [Abstract][Full Text] [Related]
16. The kidney and uremic toxin removal: glomerulus or tubule?
Masereeuw R; Mutsaers HA; Toyohara T; Abe T; Jhawar S; Sweet DH; Lowenstein J
Semin Nephrol; 2014 Mar; 34(2):191-208. PubMed ID: 24780473
[TBL] [Abstract][Full Text] [Related]
17. Optimizing pediatric dosing: a developmental pharmacologic approach.
Anderson GD; Lynn AM
Pharmacotherapy; 2009 Jun; 29(6):680-90. PubMed ID: 19476420
[TBL] [Abstract][Full Text] [Related]
18. [Progress in regulation of drug transporters and metabolic enzymes by resveratrol].
Jia YM; Liu ZH; Liu KX
Yao Xue Xue Bao; 2016 Jun; 51(6):860-5. PubMed ID: 29878738
[TBL] [Abstract][Full Text] [Related]
19. Incorporating Uremic Solute-mediated Inhibition of OAT1/3 Improves PBPK Prediction of Tenofovir Renal and Systemic Disposition in Patients with Severe Kidney Disease.
Chang SY; Huang W; Chapron A; Quiñones AJL; Wang J; Isoherranen N; Shen DD; Kelly EJ; Himmelfarb J; Yeung CK
Pharm Res; 2023 Nov; 40(11):2597-2606. PubMed ID: 37704895
[TBL] [Abstract][Full Text] [Related]
20. Altered nonrenal drug clearance in ESRD.
Nolin TD
Curr Opin Nephrol Hypertens; 2008 Nov; 17(6):555-9. PubMed ID: 18941346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
